345 related articles for article (PubMed ID: 10477554)
21. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A
Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408
[TBL] [Abstract][Full Text] [Related]
22. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
23. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
24. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro.
Ostankovitch M; Le Gal FA; Connan F; Chassin D; Choppin J; Guillet JG
Int J Cancer; 1997 Sep; 72(6):987-94. PubMed ID: 9378563
[TBL] [Abstract][Full Text] [Related]
25. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.
Vignard V; Lemercier B; Lim A; Pandolfino MC; Guilloux Y; Khammari A; Rabu C; Echasserieau K; Lang F; Gougeon ML; Dreno B; Jotereau F; Labarriere N
J Immunol; 2005 Oct; 175(7):4797-805. PubMed ID: 16177129
[TBL] [Abstract][Full Text] [Related]
26. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
27. A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide.
Derré L; Ferber M; Touvrey C; Devevre E; Zoete V; Leimgruber A; Romero P; Michielin O; Lévy F; Speiser DE
J Immunol; 2007 Dec; 179(11):7635-45. PubMed ID: 18025209
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.
Valmori D; Dutoit V; Schnuriger V; Quiquerez AL; Pittet MJ; Guillaume P; Rubio-Godoy V; Walker PR; Rimoldi D; Liénard D; Cerottini JC; Romero P; Dietrich PY
J Immunol; 2002 Apr; 168(8):4231-40. PubMed ID: 11937585
[TBL] [Abstract][Full Text] [Related]
29. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
[TBL] [Abstract][Full Text] [Related]
30. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans.
Dutoit V; Rubio-Godoy V; Pittet MJ; Zippelius A; Dietrich PY; Legal FA; Guillaume P; Romero P; Cerottini JC; Houghten RA; Pinilla C; Valmori D
J Exp Med; 2002 Jul; 196(2):207-16. PubMed ID: 12119345
[TBL] [Abstract][Full Text] [Related]
31. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide.
Pittet MJ; Speiser DE; Liénard D; Valmori D; Guillaume P; Dutoit V; Rimoldi D; Lejeune F; Cerottini JC; Romero P
Clin Cancer Res; 2001 Mar; 7(3 Suppl):796s-803s. PubMed ID: 11300475
[TBL] [Abstract][Full Text] [Related]
32. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
[TBL] [Abstract][Full Text] [Related]
33. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
[TBL] [Abstract][Full Text] [Related]
35. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition.
Dutoit V; Guillaume P; Romero P; Cerottini JC; Valmori D
Cancer Immun; 2002 Jul; 2():7. PubMed ID: 12747752
[TBL] [Abstract][Full Text] [Related]
36. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.
Zippelius A; Batard P; Rubio-Godoy V; Bioley G; Liénard D; Lejeune F; Rimoldi D; Guillaume P; Meidenbauer N; Mackensen A; Rufer N; Lubenow N; Speiser D; Cerottini JC; Romero P; Pittet MJ
Cancer Res; 2004 Apr; 64(8):2865-73. PubMed ID: 15087405
[TBL] [Abstract][Full Text] [Related]
37. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
Dietrich PY; Le Gal FA; Dutoit V; Pittet MJ; Trautman L; Zippelius A; Cognet I; Widmer V; Walker PR; Michielin O; Guillaume P; Connerotte T; Jotereau F; Coulie PG; Romero P; Cerottini JC; Bonneville M; Valmori D
J Immunol; 2003 May; 170(10):5103-9. PubMed ID: 12734356
[TBL] [Abstract][Full Text] [Related]
38. Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.
Ghosh S; Rosenthal R; Zajac P; Weber WP; Oertli D; Heberer M; Martin I; Spagnoli GC; Reschner A
Ann Surg; 2005 Dec; 242(6):851-7, discussion 858. PubMed ID: 16327495
[TBL] [Abstract][Full Text] [Related]
39. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.
Savage P; Millrain M; Dimakou S; Stebbing J; Dyson J
Tumour Biol; 2007; 28(2):70-6. PubMed ID: 17264539
[TBL] [Abstract][Full Text] [Related]
40. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
